Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Director | January 22, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date January 22, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,625,458 |
Reported balance
After 2026-01-22 transaction · row 1
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 90,000 · Balance 1,625,458 F1: On March 17, 2025, the reporting person was awarded 300,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 90,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 30,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 210,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 17, 2025, the reporting person was awarded 300,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 90,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 30,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 210,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 21:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000368 · form4.xml · nonDerivative · entry 1 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,625,458 F1 · shares: On March 17, 2025, the reporting person was awarded 300,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 90,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 30,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 210,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseWarrant (Right to Buy) · Derivative | 48,076 | $0.01 Strike: $0.60 | $480.76 |
DisclosureSEC source: 0001477932-25-007585 · form4.xml · derivative · entry 2 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,076 Underlying: Common Stock · 48,076 shares Expires 2030-10-14 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 48,076 | $0.51 | $24,518.76 |
DisclosureSEC source: 0001477932-25-007585 · form4.xml · nonDerivative · entry 1 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,535,458 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 87,382 | $0.57 | $49,999.98 |
DisclosureSEC source: 0001477932-24-007971 · form4.xml · nonDerivative · entry 1 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487,382 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| November 06, 2024 Filed Nov 6, 2024 21:34 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-006919 · form4.xml · nonDerivative · entry 2 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,000 F2 · shares: The reporting person received 1,000,000 RSUs under the Issuer's 2024 Stock Incentive Plan, subject to vesting in two equal installments of 500,000 units upon the achievement of a closing stock price target above $2.50 per share and above $5.00 per share, respectively, of the Issuer's common stock for a minimum of thirty consecutive trading days prior to November 6, 2027, which date shall be no earlier than November 6, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Vesting of the RSUs shall be accelerated to fully-vest the rights to these RSUs if the Issuer undergoes a Change of Control (as defined in the Award) at a purchase price per share of the Issuer's common stock in such transaction exceeding $2.50 per share. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| November 06, 2024 Filed Nov 6, 2024 21:34 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-006919 · form4.xml · nonDerivative · entry 1 STILL TIMOTHY I · CIK 0001200616 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 F1 · shares: The reporting person received 400,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, vesting in three installments of 133,334 units, 133,333 units, and 133,333 units on each of November 6, 2025, November 6, 2026 and November 6, 2027, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.